COPD attack; Tested positive for Covid/Pneumonia; His Immune system went down; This spontaneous case was reported by a patient and describes the occurrence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD attack) and COVID-19 (Tested positive for Covid/Pneumonia) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COPD (Had an acute COPD attack and went to the emergency room.), Emphysema and Back surgery (Patient was recovering from Back surgery.). Previously administered products included for Drug use for unknown indication: Pfizer Covid-19 vaccine on 19-Mar-2021 and Pfizer Covid-19 vaccine on 21-Apr-2021. Past adverse reactions to the above products included No adverse event with Pfizer Covid-19 vaccine and Pfizer Covid-19 vaccine.   In November 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jun-2022, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD attack) (seriousness criterion hospitalization), COVID-19 (Tested positive for Covid/Pneumonia) (seriousness criterion medically significant) and IMMUNE SYSTEM DISORDER (His Immune system went down). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 and Pneumonia, at an unspecified dose and frequency. At the time of the report, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD attack) and IMMUNE SYSTEM DISORDER (His Immune system went down) outcome was unknown and COVID-19 (Tested positive for Covid/Pneumonia) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-1 test: Positive.         No concomitant medication was reported. Company comment: This spontaneous case concerns a male patient of unknown age with current medical history of Chronic obstructive pulmonary disease and Emphysema, who experienced the unexpected, serious (Hospitalization) event of Chronic obstructive pulmonary disease and unexpected, serious (Medically significant) event of COVID-19. The exact date of onset of the events was not specified in respect to the administration of a dose of mRNA-1273, hence latency could not be assessed. The initial two doses of Pfizer were administered approximately 14 months prior, the interval between the two doses is 33 days, the third dose of mRNA-1273 was administered approximately 7 months later and booster dose of mRNA-1273 was administered after 7 months. It has been reported that the patient experienced an acute COPD attack, patient was then diagnosed with COVID-19 and Pneumonia, his pulmonologist then prescribed him with Paxlovid. The outcome of the event Chronic obstructive pulmonary disease was unknown, while the event COVID-19 has resolved at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.; Sender's Comments: This spontaneous case concerns a male patient of unknown age with current medical history of Chronic obstructive pulmonary disease and Emphysema, who experienced the unexpected, serious (Hospitalization) event of Chronic obstructive pulmonary disease and unexpected, serious (Medically significant) event of COVID-19. The exact date of onset of the events was not specified in respect to the administration of a dose of mRNA-1273, hence latency could not be assessed. The initial two doses of Pfizer were administered approximately 14 months prior, the interval between the two doses is 33 days, the third dose of mRNA-1273 was administered approximately 7 months later and booster dose of mRNA-1273 was administered after 7 months. It has been reported that the patient experienced an acute COPD attack, patient was then diagnosed with COVID-19 and Pneumonia, his pulmonologist then prescribed him with Paxlovid. The outcome of the event Chronic obstructive pulmonary disease was unknown, while the event COVID-19 has resolved at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events' seriousness retained as per medical judgment.